Dermatologicals
Refine Search
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Pharmaceutical
Beijing’s InnoCare Pharma has announced encouraging Phase II results for its novel TYK2 inhibitor, ICP-488, aimed at treating moderate-to-severe plaque psoriasis. 10 October 2024
Biotechnology
The Novo Seeds portfolio company IO Biotech has raised 127 million euros ($155 million) in a Series B financing. 13 January 2021
Biotechnology
Privately-held inflammation specialist Evommune has entered into an exclusive license agreement with the Eli Lilly subsidiary Dermira to develop and commercialize three development programs. 8 January 2021
Biotechnology
Spanish skincare specialist Almirall has partnered with gene therapy company Tyris Therapeutics to tackle orphan dermatological conditions. 8 January 2021
Biotechnology
US drugmaker AbbVie has announced positive top-line results from two Phase III studies of Skyrizi (risankizumab) in adults with active psoriatic arthritis. 6 January 2021
Pharmaceutical
As 2020 was drawing to a close, AstraZeneca announced the year’s largest M&A deal with a $39 billion bid for US rare diseases firm Alexion Pharmaceuticals. Also, Eli Lilly revealed an agreement to acquire gene therapy company Prevail Therapeutics for around $1 billion. On the research front, AbbVie presented new data on its Rinvoq, which showed superiority to Sanofi’s Dupixent in atopic dermatitis, and Novo Nordisk last week revealed it will test its diabetes drug Rybelsus (semaglutide) as a possible treatment for Alzheimer’s disease. Last Wednesday saw Gilead Sciences hand back most rights to rheumatoid arthritis drug Jyseleca (filgotinib) to Belgian partner Galapagos. 20 December 2020
Pharmaceutical
Privately-held Danish medical dermatology specialist LEO Pharma today announced that Jörg Möller will join its global leadership team as executive vice president, global research and development, effective January 1, 2021. 16 December 2020
Biotechnology
AbbVie yesterday announced positive results from the Phase III induction study, U-ACHIEVE, which showed Rinvoq (upadacitinib) 45mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) at week eight, as well as all ranked secondary endpoints, in adult patients with moderate to severe ulcerative colitis. 11 December 2020
Biotechnology
US drugmaker AbbVie and Eisai on Friday announced approval of an additional indication of Humira (adalimumab), a fully human anti-TNFalpha monoclonal antibody, for the treatment of pyoderma gangrenosum (PG). 28 November 2020
Pharmaceutical
New York’s Pfizer has announced positive top-line results from the Phase III JADE REGIMEN study of abrocitinib, with both doses meeting the primary endpoint. 12 November 2020
Pharmaceutical
Spanish drugmaker Almirall closed 6% higher on Monday after presenting its latest financial results. 9 November 2020
Biotechnology
US biotech Regeneron Pharmaceuticals exceeded analysts’ estimates on both revenue and earnings with its third-quarter financial results. 5 November 2020
Biotechnology
Whether most Americans remember November 3, 2020 with fondness depends on the result of the Presidential election, but Bristol Myers Squibb executives and shareholders will definitely have a happy memory where another outcome is concerned. 3 November 2020
Biotechnology
Swiss pharma major Novartis has strengthened its case for a US Food and Drug Administration (FDA) approval of Cosentyx (secukinumab) in pediatric psoriasis. 29 October 2020
Pharmaceutical
French drugmaker Sanofi was trading 2% lower as Thursday’s trading entered its second half. 29 October 2020
Pharmaceutical
Following safety warnings on Picato (ingenol mebutate) from regulators, including the European Medicines Agency and the US Food and Drug Administration, Danish drugmaker LEO Pharma yesterday announced it was initiating a phase-out for the product, a gel for the treatment of actinic keratosis, which is expected to be completed by year-end 2020 at the latest as follows: 28 October 2020
Pharmaceutical
USA-based BioSpecifics Technologies announced today that it has entered into a definitive merger agreement under which it will be acquired by Ireland-headquartered Endo International. 19 October 2020
Biotechnology
Spanish dermatology specialist Almirall today announced that it has signed an agreement with the French authorities to make the biologic treatment Ilumetri (tildrakizumab), a high-affinity interleukin (IL)-23p19 monoclonal antibody, available in France for the treatment of adult patients with severe plaque psoriasis who are candidates for biological systemic therapy. 13 October 2020
Pharmaceutical
Japanese drugmaker Otsuka Pharmaceuticals has submitted an application for approval of MM36 (difamilast) to the Japanese regulatory authorities. 29 September 2020
Biotechnology
Sun Pharma has announced that its Japanese subsidiary had launched Ilumya (tildrakizumab) subcutaneous injection 100mg Syringe in Japan for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies. 24 September 2020
Pharmaceutical
Privately-held Danish medical dermatology specialist LEO Pharma today said that Becki Morison will join the company, effective October 1 in the position of executive vice president, global therapeutics and value strategy. 23 September 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze